Vera Therapeutics SVP exercises 5,000 options

Vera Therapeutics, Inc. (VERA) reported that Joseph R. Young, SVP, Finance and Chief Accounting Officer, exercised stock options for 5,000 shares of Class A common stock on September 11, 2026 at an exercise price of $3.9396 per share.

Rhea-AI Filing Summary

Vera Therapeutics, Inc. (VERA) reported that Joseph R. Young, SVP, Finance and Chief Accounting Officer, exercised stock options for 5,000 shares of Class A common stock on September 11, 2026 at an exercise price of $3.9396 per share. The exercise reduced the derivative position tied to this option by 5,000 shares and increased his directly held common stock to 80,754 shares, while he continues to hold 33,589 stock options following the transaction. The option began vesting on March 9, 2022, with monthly vesting thereafter, and no Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

5,000 shares exercised/converted

Exercise 2 txns

Insider Young Joseph R

Role SVP, FINANCE, CHIEF ACCT OFFCR

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1	5,000	$0.00	$0.00
Exercise	Class A Common Stock	5,000	$3.9396	$20K

Holdings After Transaction: Stock Option (right to buy) — 33,589 contracts (Direct); Class A Common Stock — 80,754 shares (Direct)

Footnotes (1)

1. F1. 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter.

Key Figures

Options Exercised: 5,000 shares Exercise Price: $3.9396 per share Common Shares Held After Transaction: 80,754 shares +3 more

6 metrics

Options Exercised 5,000 shares Stock options for Class A common stock exercised on September 11, 2026

Exercise Price $3.9396 per share Exercise price for 5,000 stock options converted into Class A common stock

Common Shares Held After Transaction 80,754 shares Direct Class A common stock holdings of Joseph R. Young after the exercise

Options Remaining After Transaction 33,589 options Total derivative shares following the 5,000-share option exercise

Option Expiration Date April 13, 2031 Expiration date of the stock option from which 5,000 shares were exercised

Initial Cliff Vesting 25% on March 9, 2022 One-quarter of the option vested on March 9, 2022, with monthly vesting thereafter

Key Terms

Stock Option (right to buy), Class A Common Stock, vesting

3 terms

Stock Option (right to buy) financial

"Security reported as "Stock Option (right to buy)" for derivative transaction"

Class A Common Stock financial

"Underlying and acquired security titled "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

vesting financial

"1/4 of the shares subject to the option vested on March 9, 2022"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VERA disclose for Joseph R. Young?

VERA disclosed that SVP, Finance and Chief Accounting Officer Joseph R. Young exercised 5,000 stock options on September 11, 2026, acquiring 5,000 shares of Class A common stock at an exercise price of $3.9396 per share.

How many Vera Therapeutics (VERA) shares does Joseph R. Young hold after this Form 4?

After the reported transactions, Joseph R. Young directly holds 80,754 shares of Vera Therapeutics Class A common stock, as stated in the filing’s post-transaction share balance for the non-derivative holdings.

What happened to Joseph R. Young’s stock options in VERA in this filing?

He exercised 5,000 stock options for Class A common stock at $3.9396 per share, reducing the derivative position tied to that option to 33,589 options remaining after the transaction.

Was the VERA insider transaction made under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not checked, so no Rule 10b5-1 trading plan is reported for these transactions by Joseph R. Young.

What is the vesting schedule of the stock option exercised in the VERA Form 4?

According to the footnote, one-quarter of the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter, describing the ongoing vesting schedule for this option grant.

What is the expiration date of the Vera Therapeutics stock option in this Form 4?

The stock option reported in the Form 4 has an expiration date of April 13, 2031, as shown in the derivative security details for the exercised option.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:32 PM Accepted by SEC EDGAR 09/14/2026 - 04:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Joseph R

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE, CHIEF ACCT OFFCR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/11/2026		M		5,000	A	$3.9396	80,754	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.9396	09/11/2026		M			5,000	(1)	04/13/2031	Class A Common Stock	5,000	$0	33,589	D

Explanation of Responses:

1. 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter.

	/s/ Joseph R. Young	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)